Fatigue Prognostic for Survival in Certain Patients With Myelodysplastic Syndromes
the ONA take:
Self-reported fatigue severity provides prognostic information for survival independent from gold-standard risk classifications in patients with newly diagnosed higher-risk myelodysplastic syndromes, a new study published online ahead of print in the journal The Lancet Oncology has shown.
Because the clinical presentation of myelodysplastic syndromes can be highly variable, researchers sought to evaluate whether self-reported fatigue severity is prognostic for overall survival in higher-risk patients.
For the study, researchers enrolled 280 patients with myelodysplastic syndromes who were enrolled within 6 months of diagnosis with an intermediate-2-risk or high-risk score.
Results showed that the median overall survival from diagnosis was 17 months. Researchers found that high-risk International Prognostic Scoring System (IPSS) score and a higher score for fatigue were independently associated with reduced overall survival. Self-reported fatigue remained a statistically significant prognostic factor for survival in further multivariate analyses.
“Our findings suggest that fatigue assessment should be included in routine diagnostic investigation for these patients and considered as a standard baseline stratification factor in future randomized controlled trials,” the authors conclude.
Self-reported fatigue severity provides prognostic information for newly diagnosed higher-risk myelodysplastic syndromes.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|